217 related articles for article (PubMed ID: 30598078)
21. [Targeted therapies in soft-tissue and visceral sarcomas].
Emile JF
Ann Pathol; 2009 Nov; 29 Spec No 1():S81-2. PubMed ID: 19887262
[No Abstract] [Full Text] [Related]
22. Coactivated platelet-derived growth factor receptor {alpha} and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma.
Dewaele B; Floris G; Finalet-Ferreiro J; Fletcher CD; Coindre JM; Guillou L; Hogendoorn PC; Wozniak A; Vanspauwen V; Schöffski P; Marynen P; Vandenberghe P; Sciot R; Debiec-Rychter M
Cancer Res; 2010 Sep; 70(18):7304-14. PubMed ID: 20685895
[TBL] [Abstract][Full Text] [Related]
23. New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics.
Gibault L; Pérot G; Chibon F; Bonnin S; Lagarde P; Terrier P; Coindre JM; Aurias A
J Pathol; 2011 Jan; 223(1):64-71. PubMed ID: 21125665
[TBL] [Abstract][Full Text] [Related]
24. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
25. Copy Number Profiling of Brazilian Astrocytomas.
Bidinotto LT; Torrieri R; Mackay A; Almeida GC; Viana-Pereira M; Cruvinel-Carloni A; Spina ML; Campanella NC; Pereira de Menezes W; Clara CA; Becker AP; Jones C; Reis RM
G3 (Bethesda); 2016 Jul; 6(7):1867-78. PubMed ID: 27172220
[TBL] [Abstract][Full Text] [Related]
26. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
27. Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma.
Cheng L; Pandya PH; Liu E; Chandra P; Wang L; Murray ME; Carter J; Ferguson M; Saadatzadeh MR; Bijangi-Visheshsaraei K; Marshall M; Li L; Pollok KE; Renbarger JL
BMC Med Genomics; 2019 Jan; 12(Suppl 1):23. PubMed ID: 30704460
[TBL] [Abstract][Full Text] [Related]
28. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
[TBL] [Abstract][Full Text] [Related]
29. Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.
Tetzlaff MT; Singh RR; Seviour EG; Curry JL; Hudgens CW; Bell D; Wimmer DA; Ning J; Czerniak BA; Zhang L; Davies MA; Prieto VG; Broaddus RR; Ram P; Luthra R; Esmaeli B
J Pathol; 2016 Sep; 240(1):84-95. PubMed ID: 27287813
[TBL] [Abstract][Full Text] [Related]
30. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
[TBL] [Abstract][Full Text] [Related]
31. Molecular profiling of soft tissue sarcomas using next-generation sequencing: a pilot study toward precision therapeutics.
Jour G; Scarborough JD; Jones RL; Loggers E; Pollack SM; Pritchard CC; Hoch BL
Hum Pathol; 2014 Aug; 45(8):1563-71. PubMed ID: 24908143
[TBL] [Abstract][Full Text] [Related]
32. Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.
Nakano K; Takahashi S
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29510588
[TBL] [Abstract][Full Text] [Related]
33. Nutlin-3a efficacy in sarcoma predicted by transcriptomic and epigenetic profiling.
Pishas KI; Neuhaus SJ; Clayer MT; Schreiber AW; Lawrence DM; Perugini M; Whitfield RJ; Farshid G; Manavis J; Chryssidis S; Mayo BJ; Haycox RC; Ho K; Brown MP; D'Andrea RJ; Evdokiou A; Thomas DM; Desai J; Callen DF; Neilsen PM
Cancer Res; 2014 Feb; 74(3):921-31. PubMed ID: 24336067
[TBL] [Abstract][Full Text] [Related]
34. RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors.
Kohlmeyer JL; Kaemmer CA; Pulliam C; Maharjan CK; Samayoa AM; Major HJ; Cornick KE; Knepper-Adrian V; Khanna R; Sieren JC; Leidinger MR; Meyerholz DK; Zamba KD; Weimer JM; Dodd RD; Darbro BW; Tanas MR; Quelle DE
Clin Cancer Res; 2020 Jun; 26(12):2997-3011. PubMed ID: 32086342
[TBL] [Abstract][Full Text] [Related]
35. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
[TBL] [Abstract][Full Text] [Related]
36. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines.
Salawu A; Fernando M; Hughes D; Reed MW; Woll P; Greaves C; Day C; Alhajimohammed M; Sisley K
Br J Cancer; 2016 Oct; 115(9):1058-1068. PubMed ID: 27560552
[TBL] [Abstract][Full Text] [Related]
37. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
38. Next-generation sequencing reveals mutations in RB1, CDK4 and TP53 that may promote chemo-resistance to palbociclib in ovarian cancer.
El Shamieh S; Saleh F; Assaad S; Farhat F
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145688
[TBL] [Abstract][Full Text] [Related]
39. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy.
Knudsen ES; Pruitt SC; Hershberger PA; Witkiewicz AK; Goodrich DW
Trends Cancer; 2019 May; 5(5):308-324. PubMed ID: 31174843
[TBL] [Abstract][Full Text] [Related]
40. Altered expression of G1 regulatory proteins in human soft tissue sarcomas.
Yoo J; Park SY; Kang SJ; Shim SI; Kim BK
Arch Pathol Lab Med; 2002 May; 126(5):567-73. PubMed ID: 11958662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
